Dermato-Onco2024 | Identifying biomarkers in cutaneous SCC for enhanced patient screening
Vasu Divi
• 28 Oct 2024
Vasu Divi, MD, Stanford Medicine, Stanford, CA, highlights the need for better biomarkers in cutaneous squamous cell carcinoma (cSCC) to improve patient selection for clinical trials. High levels of PD-L1 expression and tumor mutational burden have been correlated to consistent responses for the risk of relapse, but they do not eliminate the possibility of false positives. This interview took place at The European Congress on Dermato-Oncology 2024 in Vienna, Austria.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
